What's Happening?
Amgen has announced positive results from a Phase 3 clinical trial of a subcutaneous formulation of TEPEZZA, aimed at treating moderate-to-severe active Thyroid Eye Disease (TED). The trial demonstrated that the subcutaneous version, delivered via an on-body
injector, matches the efficacy of the original intravenous formulation, offering a more convenient treatment option. This development addresses the logistical challenges of the IV regimen, potentially increasing patient adoption and expanding Amgen's market share in the TED space.
Why It's Important?
The introduction of a subcutaneous TEPEZZA formulation represents a significant shift in the treatment of Thyroid Eye Disease, offering patients a less burdensome option that can be administered at home. This advancement could lead to increased patient adherence and broaden the treatment's reach to those who previously avoided the IV regimen due to its complexity. Amgen's success in this trial strengthens its position in the biologic innovation sector and could drive commercial expansion, especially as it faces competition from other companies developing similar treatments.
What's Next?
Amgen plans to file a supplemental Biologics License Application (sBLA) for the subcutaneous TEPEZZA, with expectations for a streamlined approval process given the FDA's familiarity with wearable injectors. The company is preparing for a potential commercial launch by late 2026 or early 2027, focusing on transitioning patients from the IV to the SC version and expanding its market reach.
